ER negative

P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

These findings advance our understanding of genetic susceptibility to different cancers. Future work in larger, more diverse GWAS, coupled with more comprehensive annotation atlases, is essential to expand upon and validate our results.

This profile supported the diagnosis of primary vulvar apocrine adenocarcinoma, allowing for appropriate surgical management and successful excision of the lesion. This case highlights the diagnostic complexity of vulvar adenocarcinomas and underscores the importance of systematic clinicopathologic evaluation, particularly in patients with a history of malignancy.

ER and L1CAM appear to have comparable prognostic value in no specific molecular profile endometrial cancer, and their combination with tumor grade enhances risk stratification. A combined marker including ER, L1CAM, and grade may improve risk stratification beyond either pair of markers and may be used to tailor treatment.

SLC7A5 expression serves as an integral marker of breast cancer aggressiveness, associated with unfavorable immunophenotypes and independently predictive of lymphogenous metastasis. Its assessment may improve risk stratification and help identify candidates for LAT1 inhibitor-targeted therapy.

P3, N=531, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed

The TCHP regimen (docetaxel, carboplatin, trastuzumab, pertuzumab) demonstrated efficacy in clinical trials; however, real-world evidence remains limited. A median of three ER visits per patient was recorded, with hospitalization required in 42 patients, primarily for neutropenic fever and diarrhea. In this real‑world cohort, TCHP achieved a moderate pCR rate (45.5%), lower than clinical trial reports, with HER2 IHC 3+ and ER/PR‑negative status predicting response, but substantial toxicity-including frequent emergency visits and hospitalization, highlighting the need for improved patient selection, strengthened supportive care, and consideration of de‑escalation strategies to maintain efficacy while reducing morbidity.

This study represents the first MR and colocalization investigation of hypertension and BC risk in a sub-Saharan African population. Although no evidence of a direct genetic causal relationship was identified, the combined MR and colocalization findings suggest that previously reported associations may be driven by nongenetic metabolic or vascular mechanisms rather than shared inherited genetic determinants. Further studies in larger and more diverse populations are warranted to confirm these findings and explore underlying biological pathways.

In our study, IDO expression on tumor cells was predominantly observed in TNBC and was found to correlate with PD-L1 expression in the lymphocytic and stromal compartments. Furthermore, expression of PD-L1 among lymphocytes was found to independently correlate with unfavorable clinicopathological parameters, including high proliferation rate and negative hormone receptor status.

The statuses of ER and PR carry independent prognostic and therapeutic implications beyond those of traditional clinicopathologic risk factors. Given that ER and PR statuses are routinely collected for patients with DCIS, incorporation of these variables into clinicopathologic risk classification systems is warranted.

In this retrospective cohort study, neoadjuvant 12wTCHP was well tolerated and associated with high pCR and low early recurrence rates. These findings are hypothesis-generating and support further evaluation of de-escalated 12wTCHP regimen in selected patients.

ER-low breast cancer challenges the traditional binary classification of hormone receptor-positive/-negative disease. Diagnostic variability, biological heterogeneity, and therapeutic ambiguity justify the need for standardized pathological assessment, biomarker-driven stratification, and dedicated prospective trials to refine management and improve outcomes.